AskMed

CHA₂DS₂-VASc score interpretation: what each score from 0 to 9 means

CHA₂DS₂-VASc score interpretation depends on sex: a score of 0 in men or 1 in women is low risk, 1 in men or 2 in women is intermediate risk, and 2 or more in men or 3 or more in women is high risk, where the 2023 ACC/AHA/ACCP/HRS guideline recommends anticoagulation. Here is what every score from 0 to 9 means, the stroke rates published for each score, what the ESC and US guidelines say about each band, and the scoring mistakes that put patients in the wrong band.

Open the CHA₂DS₂-VASc calculator

What a CHA₂DS₂-VASc score means

A CHA₂DS₂-VASc score counts stroke risk factors in a person with atrial fibrillation (AF), and its meaning is a rank: the higher the score, the higher the expected yearly risk of stroke or systemic thromboembolism without anticoagulation. Lip and colleagues described the score in Chest in 2010 and tested it in 1,084 patients from the Euro Heart Survey on AF. Congestive heart failure, hypertension, diabetes, vascular disease, age 65 to 74 and female sex score 1 point each, while age 75 or older and prior stroke, TIA or thromboembolism score 2 points each, so the full CHA₂DS₂-VASc score range is 0 to 9. In that first cohort, patients the new scheme rated low risk had no thromboembolic events, and the event rate rose with each higher score (P for trend 0.003). The 2023 ACC/AHA/ACCP/HRS guideline groups the scores into three bands of estimated annual risk: low (about under 1%), intermediate (about 1% to 2%) and high (about 2% or more).

The score says nothing about bleeding risk, which both guidelines assess separately, for example with the HAS-BLED score.

The CHA₂DS₂-VASc score range for men and women

The CHA₂DS₂-VASc score range is not the same for both sexes, so the same number can mean different things in men and women. Female sex adds 1 point, so a woman scores at least 1 and can reach 9, while a man scores from 0 to 8. The 2023 ACC/AHA/ACCP/HRS guideline therefore sets each band one point higher for women: low risk is 0 in men and 1 in women, intermediate risk is 1 in men and 2 in women, and high risk is 2 or more in men and 3 or more in women. A woman whose only point is her sex sits in the same low band as a man with no points at all. Read the other way, a score of 2 is high risk for a man but intermediate for a woman, and a score of 1 is intermediate for a man but low for a woman. From 3 upwards, every score is high risk for both sexes.

CHA₂DS₂-VASc bands by sex Men 0 1 2 3 4 5 6 7 8 – Women – 1 2 3 4 5 6 7 8 9 Low Intermediate High Not possible
Each CHA₂DS₂-VASc score from 0 to 9 in the risk bands of the 2023 ACC/AHA/ACCP/HRS guideline: low (about under 1% a year), intermediate (about 1% to 2%) and high (about 2% or more). A man cannot score 9 and a woman cannot score 0.

Stroke rates for each CHA₂DS₂-VASc score

Stroke and thromboembolism rates for each CHA₂DS₂-VASc score differ several-fold between studies, so any rate quoted for a score belongs to the population it was measured in. Two large cohorts of patients with AF who were not taking anticoagulants show the spread. The ATRIA study (Singer and colleagues, 2013) followed 10,927 patients with nonvalvular AF at Kaiser Permanente Northern California, diagnosed in 1996 and 1997, through 32,609 person-years off warfarin and counted 685 ischemic strokes and other arterial thromboembolic events; the 2023 US guideline reproduces its table. Olesen and colleagues (BMJ, 2011) used Danish national registries to follow 73,538 patients discharged from hospital with non-valvular AF between 1997 and 2006 who were not treated with a vitamin K antagonist or heparin, counting hospital admission or death from ischaemic stroke, peripheral artery embolism or pulmonary embolism. The Danish hospital cohort had the higher rate at every score, but in both cohorts the rate rose as the score went up.

ScoreATRIA (events / person-years)Danish registry, first year
00.04 (1 / 2,493)0.78
10.55 (21 / 3,806)2.01
20.83 (46 / 5,560)3.71
31.66 (121 / 7,305)5.92
42.80 (193 / 6,898)9.27
54.31 (175 / 4,057)15.26
64.77 (85 / 1,783)19.74
74.82 (24 / 498)21.50
87.82 (14 / 179)22.38
916.62 (5 / 30)23.64

Both columns give events per 100 person-years. Neither is split by sex: each row mixes the men and women who reached that total. The top scores rest on few patients. ATRIA had 30 person-years and 5 events at a score of 9, and the Danish 95% confidence interval at 9 ran from 10.62 to 52.61 events per 100 person-years.

Low risk: 0 in men, 1 in women

A CHA₂DS₂-VASc score of 0 in a man or 1 in a woman is the low band, which the 2023 ACC/AHA/ACCP/HRS guideline puts at an annual stroke risk of about under 1%. In the ATRIA cohort, a score of 0 carried 0.04 events per 100 person-years (1 event in 2,493 person-years), and a score of 1, which mixes women with no other risk factor and men with one, carried 0.55. In the Danish registry, a score of 0 carried 0.78 in the first year, and women whose only point was their sex carried 1.24. Neither guideline recommends anticoagulation in this band. The US guideline's recommendations for anticoagulation start at the intermediate band, and it states that in patients with AF and no risk factors for stroke, aspirin alone is of no benefit for preventing thromboembolism (Class 3: No Benefit). The 2024 ESC guideline offers oral anticoagulation to eligible patients except those at low risk, and its thresholds for anticoagulation start at a CHA₂DS₂-VA of 1.

A low score needs checking again over time. A 64-year-old man with no risk factors scores 0, and the same man scores 1 at 65 without any new diagnosis. The US guideline recommends reevaluating stroke risk at periodic intervals, typically once a year, and sooner when the clinical picture changes (Class 1).

Intermediate risk: 1 in men, 2 in women

A CHA₂DS₂-VASc score of 1 in a man or 2 in a woman is the intermediate band, an estimated annual risk of about 1% to under 2% in the 2023 ACC/AHA/ACCP/HRS guideline, where anticoagulation is reasonable to prevent stroke and systemic thromboembolism (Class 2a). The same guideline says that patients in this band who remain uncertain can benefit from weighing factors the score leaves out (Class 2a), such as a higher AF burden or long duration, persistent or permanent AF, obesity, poorly controlled hypertension, an eGFR under 45, proteinuria and an enlarged left atrium. The 2024 ESC guideline reaches the same patients through CHA₂DS₂-VA, where a score of 1 should be considered an indicator of elevated thromboembolic risk for oral anticoagulation (Class IIa). Here the single factor matters most. In the Danish registry, the first-year rate at a score of 1 ranged from 0.75 per 100 person-years when the point was vascular disease to 2.88 for age 65 to 74 and 3.47 for diabetes.

High risk: 2 or more in men, 3 or more in women

A CHA₂DS₂-VASc score of 2 or more in a man, or 3 or more in a woman, is the high band, an estimated annual risk of about 2% or more. For this band the 2023 ACC/AHA/ACCP/HRS guideline recommends anticoagulation to prevent stroke and systemic thromboembolism (Class 1, Level A), and it states that the AF pattern, whether paroxysmal, persistent, long-standing persistent or permanent, should not change that decision. The 2024 ESC guideline recommends a CHA₂DS₂-VA of 2 or more as the indicator of elevated thromboembolic risk for starting oral anticoagulation (Class I), which covers the same men and women. Both guidelines advise against antiplatelet therapy as an alternative to anticoagulation (US Class 3: Harm, ESC Class III). A bleeding risk score does not move a patient out of this band: the US guideline says bleeding scores should be used to find and modify bleeding risk factors, not on their own to decide who is eligible for anticoagulation.

The high band covers a wide range of risk. In ATRIA, rates went from 0.83 events per 100 person-years at a score of 2 to 4.31 at 5 and 16.62 at 9; in the Danish registry, from 3.71 to 15.26 and 23.64. How a score is reached matters as well: at a score of 2 in the Danish data, age 75 or older alone carried 4.75 events per 100 person-years in the first year, while a prior thromboembolism alone carried 16.07.

Worked example on the calculator

Take a 58-year-old woman with AF and type 2 diabetes treated with a glucose-lowering drug, and no heart failure, hypertension, vascular disease or prior stroke. The CHA₂DS₂-VASc calculator opens on a woman aged 65 to 74 with hypertension, so keep Female, set age to Under 65, untick Hypertension and tick Diabetes. The calculator then shows a CHA₂DS₂-VASc score of 2 of 9 points, the band "Intermediate · about 1% to 2% a year", and a CHA₂DS₂-VA of 1 under the result. She scores 1 point for diabetes and 1 for female sex. Under the 2023 ACC/AHA/ACCP/HRS guideline she is in the intermediate band, where anticoagulation is reasonable (Class 2a); under the 2024 ESC guideline her CHA₂DS₂-VA of 1 means anticoagulation should be considered (Class IIa). A man with the same history would score 1, in the same band. The published rates for her score vary widely, which is why the band, not one percentage, carries the decision.

In ATRIA a total of 2 carried 0.83 events per 100 person-years, and in the Danish registry 3.71. For the exact pair of diabetes and female sex, the Danish first-year rate was 1.11, with a 95% confidence interval from 0.16 to 7.85 because few patients had that combination. At 65 she gains the age point: change the age to 65–74 and the CHA₂DS₂-VASc calculator shows 3, "High · about 2% a year or more", and a CHA₂DS₂-VA of 2, the threshold for a Class 1 recommendation in the US guideline and Class I in the ESC guideline.

Common CHA₂DS₂-VASc scoring mistakes

Most CHA₂DS₂-VASc errors come from the definitions behind each letter rather than the arithmetic, and each one can move a patient across a band. The first is reading a woman's score against men's thresholds: a woman scoring 2 is intermediate risk, not high, and a woman scoring 1 is low. The second is adding both age points: a patient aged 75 or older scores 2 for age in total, never 3. The third is leaving out treated hypertension. In the original definition, hypertension means a resting blood pressure over 140/90 mmHg on at least 2 occasions or current antihypertensive treatment, so a well-controlled patient on treatment still scores the point. The fourth is undercounting the stroke item: a prior transient ischemic attack, peripheral embolism or pulmonary embolism scores the same 2 points as an ischemic stroke. The fifth is missing vascular disease, which includes prior myocardial infarction, angina, PCI, CABG and peripheral vascular disease.

  • Mixing the two scores. A woman's CHA₂DS₂-VA is always 1 point lower than her CHA₂DS₂-VASc, so read each number only against its own guideline's thresholds; the guide CHA₂DS₂-VASc vs CHA₂DS₂-VA explains why the ESC changed scores.
  • Scoring once and never again. Both guidelines recommend reassessing thromboembolic risk at periodic intervals (US Class 1, ESC Class I), because birthdays at 65 and 75 and new diagnoses add points.
  • Counting heart failure on symptoms alone. The original definition, as the 2023 US guideline reproduces it, needs signs and symptoms of heart failure confirmed by measurements that show objective evidence of cardiac dysfunction.

Limits of CHA₂DS₂-VASc score interpretation

The CHA₂DS₂-VASc score ranks risk moderately well, but its bands do not fit every patient or every population. Its C-statistic was 0.606 in the Euro Heart Survey and 0.70 across the full 0 to 9 range in ATRIA. Grouped into the published low, intermediate and high categories of 0, 1 and 2 or more, it fell to 0.58 in ATRIA, because 81% of person-years landed in the high category. The score also does not apply where another condition sets the risk. The 2023 ACC/AHA/ACCP/HRS guideline recommends long-term anticoagulation in AF with rheumatic mitral stenosis, or mitral stenosis of moderate or greater severity, independent of the score, and says the score should not be applied in hypertrophic cardiomyopathy, where risk is roughly that of a score of 3. The 2024 ESC guideline recommends oral anticoagulation in all patients with AF and hypertrophic cardiomyopathy or cardiac amyloidosis, regardless of CHA₂DS₂-VA (Class I).

The published rates come from patients who were not taking anticoagulants in patients diagnosed with AF between 1996 and 2006, so they describe untreated risk in those populations rather than an exact forecast for a patient seen today.

Questions

What is a normal CHA₂DS₂-VASc score?

There is no normal value, only a lowest band: 0 in men and 1 in women, an estimated annual risk of about under 1% in the 2023 ACC/AHA/ACCP/HRS guideline. Neither the US nor the ESC guideline recommends anticoagulation for stroke prevention at that level.

What does a CHA₂DS₂-VASc score of 2 mean?

For a man, 2 is the high band, where the US guideline recommends anticoagulation (Class 1). For a woman, 2 is the intermediate band, where anticoagulation is reasonable (Class 2a). In the cohorts above, a score of 2 carried 0.83 (ATRIA) and 3.71 (Danish registry) events per 100 person-years.

Is CHADS-VASc score interpretation the same as CHA₂DS₂-VASc?

Yes. "CHADS-VASc" and "CHADS2-VASc" are informal spellings of CHA₂DS₂-VASc, read with the same bands. The older CHADS₂ score is different: it runs from 0 to 6 and leaves out vascular disease, age 65 to 74 and female sex.

Does paroxysmal AF change the meaning of the score?

No. The 2023 ACC/AHA/ACCP/HRS guideline recommends basing stroke prevention on the estimated risk whether AF is paroxysmal, persistent, long-standing persistent or permanent (Class 1).

Can AskMed explain a CHA₂DS₂-VASc score with sources?

Yes. AskMed answers from guidelines and journals with a citation after every claim, and it does not give doses. Get it on the App Store or Google Play, or use it on the web.

Sources

  1. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-1584
  2. Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2(3):e000250. doi:10.1161/JAHA.113.000250
  3. Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. doi:10.1136/bmj.d124
  4. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation. 2024;149(1):e1–e156. doi:10.1161/CIR.0000000000001193
  5. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2024;45(36):3314–3414. doi:10.1093/eurheartj/ehae176

Cited medical answers
you can trust.

AskMed on iPhone, iPad, Android and the web.